Literature DB >> 30908155

Atrial Fibrillation and Brain Magnetic Resonance Imaging Abnormalities.

Jeremy P Berman1, Faye L Norby2, Thomas Mosley3, Elsayed Z Soliman4, Rebecca F Gottesman5, Pamela L Lutsey2, Alvaro Alonso6, Lin Y Chen1.   

Abstract

Background and Purpose- Atrial fibrillation (AF) is associated with dementia independent of clinical stroke. The mechanisms underlying this association remain unclear. In a community-based cohort, the ARIC study (Atherosclerosis Risk in Communities), we evaluated (1) the longitudinal association of incident AF and (2) the cross-sectional association of prevalent AF with brain magnetic resonance imaging (MRI) abnormalities. Methods- The longitudinal analysis included 963 participants (mean age, 73±4.4 years; 62% women; 51% black) without prevalent stroke or AF who underwent a brain MRI in 1993 to 1995 and a second MRI in 2004 to 2006 (mean, 10.6±0.8 years). Outcomes included subclinical cerebral infarctions, sulcal size, ventricular size, and, for the cross-sectional analysis, white matter hyperintensity volume and total brain volume. Results- In the longitudinal analysis, 29 (3.0%) participants developed AF after the first brain MRI. Those who developed AF had higher odds of increase in subclinical cerebral infarctions (odds ratio [OR], 3.08; 95% CI, 1.39-6.83), worsening sulcal grade (OR, 3.56; 95% CI, 1.04-12.2), and worsening ventricular grade (OR, 9.34; 95% CI, 1.24-70.2). In cross-sectional analysis, of 969 participants, 35 (3.6%) had prevalent AF at the time of the 2004 to 2006 MRI scan. Those with AF had greater odds of higher sulcal (OR, 3.9; 95% CI, 1.7-9.1) and ventricular grade (OR, 2.4; 95% CI, 1.0-5.7) after multivariable adjustment and no difference in white matter hyperintensity or total brain volume. Conclusions- AF is independently associated with increase in subclinical cerebral infarction and worsening sulcal and ventricular grade-morphological changes associated with aging and dementia. More research is needed to define the mechanisms underlying AF-related neurodegeneration.

Entities:  

Keywords:  atrial fibrillation; cognitive dysfunction; dementia; magnetic resonance imaging; research

Mesh:

Year:  2019        PMID: 30908155      PMCID: PMC6662638          DOI: 10.1161/STROKEAHA.118.024143

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  32 in total

1.  Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence.

Authors:  Yoko Miyasaka; Marion E Barnes; Bernard J Gersh; Stephen S Cha; Kent R Bailey; Walter P Abhayaratna; James B Seward; Teresa S M Tsang
Journal:  Circulation       Date:  2006-07-03       Impact factor: 29.690

2.  Cerebral blood flow before and after cardioversion of atrial fibrillation.

Authors:  P Petersen; J Kastrup; R Videbaek; G Boysen
Journal:  J Cereb Blood Flow Metab       Date:  1989-06       Impact factor: 6.200

3.  Atrial fibrillation is an independent determinant of low cognitive function: a cross-sectional study in elderly men.

Authors:  L Kilander; B Andrén; H Nyman; L Lind; M Boberg; H Lithell
Journal:  Stroke       Date:  1998-09       Impact factor: 7.914

4.  Silent brain infarcts and the risk of dementia and cognitive decline.

Authors:  Sarah E Vermeer; Niels D Prins; Tom den Heijer; Albert Hofman; Peter J Koudstaal; Monique M B Breteler
Journal:  N Engl J Med       Date:  2003-03-27       Impact factor: 91.245

5.  Vascular risk factors and longitudinal changes on brain MRI: the ARIC study.

Authors:  D S Knopman; A D Penman; D J Catellier; L H Coker; D K Shibata; A R Sharrett; T H Mosley
Journal:  Neurology       Date:  2011-05-04       Impact factor: 9.910

6.  Incidence of and risk factors for atrial fibrillation in older adults.

Authors:  B M Psaty; T A Manolio; L H Kuller; R A Kronmal; M Cushman; L P Fried; R White; C D Furberg; P M Rautaharju
Journal:  Circulation       Date:  1997-10-07       Impact factor: 29.690

7.  Association Between Atrial Fibrillation and Dementia in the General Population.

Authors:  Renée F A G de Bruijn; Jan Heeringa; Frank J Wolters; Oscar H Franco; Bruno H C Stricker; Albert Hofman; Peter J Koudstaal; M Arfan Ikram
Journal:  JAMA Neurol       Date:  2015-11       Impact factor: 18.302

8.  Atrial fibrillation is associated with reduced brain volume and cognitive function independent of cerebral infarcts.

Authors:  Hrafnhildur Stefansdottir; David O Arnar; Thor Aspelund; Sigurdur Sigurdsson; Maria K Jonsdottir; Haukur Hjaltason; Lenore J Launer; Vilmundur Gudnason
Journal:  Stroke       Date:  2013-02-26       Impact factor: 7.914

9.  Silent cerebral infarction in patients with nonrheumatic atrial fibrillation. The Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators.

Authors:  M D Ezekowitz; K E James; S M Nazarian; J Davenport; J P Broderick; S R Gupta; V Thadani; M L Meyer; S L Bridgers
Journal:  Circulation       Date:  1995-10-15       Impact factor: 29.690

10.  Association of white matter hyperintensity volume with decreased cognitive functioning: the Framingham Heart Study.

Authors:  Rhoda Au; Joseph M Massaro; Philip A Wolf; Megan E Young; Alexa Beiser; Sudha Seshadri; Ralph B D'Agostino; Charles DeCarli
Journal:  Arch Neurol       Date:  2006-02
View more
  2 in total

1.  PR interval duration is associated with the presence of white matter hyperintensities: Insights from the epidemiologic LIFE-Adult Study.

Authors:  Jelena Kornej; Katrin Friedrich; Matthias L Schroeter; A Veronica Witte; Maryna Polyakova; Arno Villringer; Markus Löffler; Samira Zeynalova
Journal:  PLoS One       Date:  2022-06-15       Impact factor: 3.752

2.  Atrial Fibrillation, Stroke, and Silent Cerebrovascular Disease: A Population-based MRI Study.

Authors:  Lina Rydén; Simona Sacuiu; Hanna Wetterberg; Jenna Najar; Xinxin Guo; Silke Kern; Anna Zettergren; Sara Shams; Joana B Pereira; Lars-Olof Wahlund; Eric Westman; Ingmar Skoog
Journal:  Neurology       Date:  2021-09-14       Impact factor: 9.910

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.